Drug Details

General Information of the Drug (ID: DR2202)
Name
Candesartan cilexetil
Synonyms
Candesartan cilexetil; 145040-37-5; Atacand; TCV-116; Amias; Parapres; Kenzen; candesartancilexetil; CANDESARTAN CILEXTIL; TCV 116; C33H34N6O6; CHEMBL1014; CHEBI:3348; 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate; TCY 116; MFCD00871371; 1-(cyclohexyloxycarbonyloxy)ethyl 1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate; 1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate; 1-(((cyclohexyloxy)carbonyl)oxy)ethyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate; 2-Ethoxy-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester; 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl 2-ethoxy-1-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-benzimidazole-7-carboxylate; 2-ETHOXY-1-[[2'-(2H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1H-BENZIMIDAZOLE-7-CARBOXYLIC ACID 1-[[(CYCLOHEXYLOXY)CARBONYL]OXY]ETHYL ESTER; Candesartan cilexetil [USAN]; Racanda; Candesartan hexetil; 1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate; Atacand (TN); candesartan cilexitil; Spectrum_001707; Candesartan (Cilexetil); DSSTox_CID_239; Spectrum2_000485; Spectrum3_000996; Spectrum4_001124; Spectrum5_001462; DSSTox_RID_85567; DSSTox_GSID_20239; SCHEMBL40831; BSPBio_002691; KBioGR_001607; KBioSS_002187; 1H-Benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)-, hydroxide, inner salt, (+-)-; Candesartan Cilexetil-[d11]; MLS004774127; Candesartan cilexetil , 97%; SPECTRUM1504261; SPBio_000349; GTPL8352; Candesartan cilexetil (Atacand); DTXSID5020239; KBio2_002187; KBio2_004755; KBio2_007323; KBio3_001911; EBD4212; HMS1922J09; HMS2093E20; HMS3651I08; Pharmakon1600-01504261; Candesartan cilexetil (JP17/USP); BCP22050; Tox21_302202; AC-204; BDBM50318907; CCG-39530; NSC758697; s2037; STL451065; AKOS015894954; AKOS015920180; AB07617; AM90293; BCP9000480; CCG-222334; DB00796; DS-1302; KS-1147; NSC 758697; NSC-758697; VA10473; Candesartan cilexetil, >=98% (HPLC); NCGC00095123-01; NCGC00095123-02; NCGC00095123-03; NCGC00095123-05; NCGC00095123-10; NCGC00095123-16; NCGC00255218-01; (+-)-1-Hydroxyethyl 2-ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylate, cyclohexyl carbonate (ester); 1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate; 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester, (+-)-; AK-75900; HY-17505; SMR003500784; SBI-0206767.P001; AB0012012; C-265; CAS-145040-37-5; FT-0602914; SW220041-1; A-2005; C07709; D00626; J10436; AB01274805-01; AB01274805_02; AB01274805_03; 040C375; H212/91; L006257; SR-05000001976; Camptothecine, Antibiotic for Culture Media Use Only; Q-200786; SR-05000001976-1; BRD-A65671304-001-02-6; BRD-A65671304-001-03-4; Q27075664; Candesartan 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester; Candesartan cilexetil, European Pharmacopoeia (EP) Reference Standard; Candesartan cilexetil, United States Pharmacopeia (USP) Reference Standard; Candesartan cilexetil for peak identification, European Pharmacopoeia (EP) Reference Standard; Candesartan cilexetil for system suitability, European Pharmacopoeia (EP) Reference Standard; Candesartan Cilexetil, Pharmaceutical Secondary Standard; Certified Reference Material; (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methylbenzimidazole-7-carboxylate; (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methylbenzimidazole-7-carboxylate; 1-(Cyclohexyloxycarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazol-7-carboxylate; 1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate; 1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl] methyl]benzimidazole-4-carboxylate; 1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate.; 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester; 2-Ethoxy-1-[2'-(1H-tetrazole-5-yl)-4-biphenylylmethyl]-1H-benzimidazole-7-carboxylic acid 1-(cyclohexyloxycarbonyloxy)ethyl ester; 2-Ethoxy-3-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester; 2-Ethoxy-3-[2''-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester; 2-ethoxy-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic acid 1-cyclohe
    Click to Show/Hide
Molecular Type
Small molecule
Disease Hypertension [ICD-11: BA00] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C33H34N6O6
PubChem CID
2540
Canonical SMILES
CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)OC(C)OC(=O)OC6CCCCC6
InChI
1S/C33H34N6O6/c1-3-42-32-34-28-15-9-14-27(31(40)43-21(2)44-33(41)45-24-10-5-4-6-11-24)29(28)39(32)20-22-16-18-23(19-17-22)25-12-7-8-13-26(25)30-35-37-38-36-30/h7-9,12-19,21,24H,3-6,10-11,20H2,1-2H3,(H,35,36,37,38)
InChIKey
GHOSNRCGJFBJIB-UHFFFAOYSA-N
CAS Number
CAS 145040-37-5
ChEBI ID
CHEBI:3348
DrugBank ID
DB00796
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Trandolapril      Homo sapiens     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Clinical trial
                    Experimental
                    Result(s)		 Combination therapy with trandolapril and candesartan cilexetil has an additive effect on the reduction of microalbuminuria in microalbuminuric normotensive type 2 diabetes patients.
Target and Pathway
Target(s) Integrin alpha-V (ITGAV)  Molecule Info  [3]
Integrin beta-3 (ITGB3)  Molecule Info  [3]
Integrin beta-5 (ITGB5)  Molecule Info  [3]
KEGG Pathway Rap1 signaling pathway Click to Show/Hide
2 Phagosome
3 PI3K-Akt signaling pathway
4 Osteoclast differentiation
5 Focal adhesion
6 ECM-receptor interaction
7 Platelet activation
8 Hematopoietic cell lineage
9 Regulation of actin cytoskeleton
10 Thyroid hormone signaling pathway
11 Proteoglycans in cancer
12 MicroRNAs in cancer
13 Hypertrophic cardiomyopathy (HCM)
14 Arrhythmogenic right ventricular cardiomyopathy (ARVC)
15 Dilated cardiomyopathy
16 Cell adhesion molecules (CAMs)
17 Pathways in cancer
18 Small cell lung cancer
NetPath Pathway Leptin Signaling Pathway Click to Show/Hide
Panther Pathway Integrin signalling pathway Click to Show/Hide
2 CCKR signaling map ST
Pathway Interaction Database IL4-mediated signaling events Click to Show/Hide
2 Integrin family cell surface interactions
3 Signaling events mediated by PTP1B
4 Beta3 integrin cell surface interactions
5 S1P3 pathway
6 Osteopontin-mediated events
7 Nectin adhesion pathway
8 Arf6 signaling events
9 S1P1 pathway
10 Integrins in angiogenesis
11 Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
12 PDGFR-beta signaling pathway
13 Signaling events mediated by VEGFR1 and VEGFR2
14 Ephrin B reverse signaling
15 Beta1 integrin cell surface interactions
16 Arf6 trafficking events
17 CXCR4-mediated signaling events
18 Plexin-D1 Signaling
19 PDGFR-alpha signaling pathway
20 Beta5 beta6 beta7 and beta8 integrin cell surface interactions
21 Signaling events mediated by focal adhesion kinase
Reactome Platelet degranulation Click to Show/Hide
2 Elastic fibre formation
3 PECAM1 interactions
4 Molecules associated with elastic fibres
5 Integrin cell surface interactions
6 Syndecan interactions
7 ECM proteoglycans
8 Integrin alphaIIb beta3 signaling
9 GRB2:SOS provides linkage to MAPK signaling for Integrins
10 p130Cas linkage to MAPK signaling for integrins
11 VEGFA-VEGFR2 Pathway
12 MAP2K and MAPK activation
13 Cross-presentation of particulate exogenous antigens (phagosomes)
14 Laminin interactions
WikiPathways Monoamine Transport Click to Show/Hide
2 TGF beta Signaling Pathway
3 Osteoblast Signaling
4 Focal Adhesion
5 Hematopoietic Stem Cell Differentiation
6 Human Complement System
7 Syndecan interactions
8 Extracellular matrix organization
9 Elastic fibre formation
10 Primary Focal Segmental Glomerulosclerosis FSGS
11 Arrhythmogenic Right Ventricular Cardiomyopathy
12 Integrin-mediated Cell Adhesion
13 L1CAM interactions
14 Integrin cell surface interactions
15 Integrin alphaIIb beta3 signaling
16 Cell surface interactions at the vascular wall
17 Serotonin Transporter Activity
18 Osteopontin Signaling
19 Osteoclast Signaling
20 Class I MHC mediated antigen processing & presentation
References
Reference 1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2009
Reference 2 Combination therapy of trandolapril and candesartan cilexetil reduces microalbuminuria and urinary endothelin-1 excretion in patients with type 2 diabetes. Clin Exp Nephrol. 2002 Sep;6(3):135-9.
Reference 3 Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with alphavbeta3 and alphavbeta5 integrins. Cancer Res. 2005 May 15;65(10):4353-61.
 Download Picture         KEGG Link